Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and AdolescentsShibadas Biswal(Takeda (United States)), Derek Wallace(Hospital del Niño)New England Journal of MedicineNovember 6, 201910.1056/nejmoa1903869Cited by 378SaveCiteExport RISWatch citationsRelated PapersLong-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial|The Lancet Global Health|2024|208